News | May 14, 2026
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The standout story remains Wegovy, particularly its new oral formulation
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Lifts full-year outlook as obesity drug boom accelerates
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The company posted revenue of Rs. 703 crore in Q4 FY26
But acquisition charges drag earnings into loss
Subscribe To Our Newsletter & Stay Updated
